Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586427 · ClinicalTrials.gov registry record · Phase 2
AGN-241751 in the Treatment of Major Depressive Disorder
A Phase 2 study of Depressive Disorder, Major, sponsored by Syndeio Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT03586427 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Syndeio Biosciences. The registered enrollment target is 251 participants, roughly in line with the 237-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target. The trial reports 20 study locations across 9 states.
The verdict
NCT03586427, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Syndeio Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AGN-241751
Study Locations (20)
California
- Synexus US - Cerritos - Cerritos
- Wake Research - Pharmacology Research Institute - Encino
- Wake Research - Pharmacology Research Institute - Newport Beach
- Pacific Research Partners, LLC - Oakland
- North County Clinical Research, Inc. - Oceanside
- Collaborative Neuroscience Network - Torrance
- Elite Clinical Trials, Inc. - Wildomar
New York
- Neurobehavioral Research, Inc - Cedarhurst
- Synexus US - Queens - Jamaica
- Eastside Comprehensive Medical Center - New York
- Finger Lakes Clinical Research - Rochester
Georgia
- Synexus US - Atlanta - Atlanta
- Atlanta Center for Medical Research - Atlanta
New Jersey
- Hassman Research Institute - Berlin
- Center for Emotional Fitness - Cherry Hill
Arkansas
- Health Initiatives Research PLLC - Fayetteville
Illinois
- Pillar Clinical Research - Lincolnwood
Massachusetts
- Boston Clinical Trials - Boston
Ohio
- Neuro-Behavioral Clinical Research, Inc - North Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2019-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03586427
The ClinicalTrials.gov registry entry for NCT03586427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 237-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target. The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03586427 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Georgia.
Frequently Asked Questions
What is clinical trial NCT03586427 about?
NCT03586427 is a clinical study titled "AGN-241751 in the Treatment of Major Depressive Disorder". The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of AGN-241751 compared with placebo in participants with Major Depressive Disorder (MDD).
What is the current status of trial NCT03586427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2018-06-13. Estimated completion is 2019-08-21.
What conditions does trial NCT03586427 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT03586427?
The interventions under investigation include: Placebo (DRUG), AGN-241751 (DRUG).
Who is sponsoring clinical trial NCT03586427?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03586427 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.